JP2015508068A5 - - Google Patents

Info

Publication number

JP2015508068A5

JP2015508068A5 JP2014556085A JP2014556085A JP2015508068A5 JP 2015508068 A5 JP2015508068 A5 JP 2015508068A5 JP 2014556085 A JP2014556085 A JP 2014556085A JP 2014556085 A JP2014556085 A JP 2014556085A JP 2015508068 A5 JP2015508068 A5 JP 2015508068A5

Authority

JP

Japan

Prior art keywords

fibrosis

compound

pharmaceutical preparation

composition

amino

Prior art date

2013-02-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000825 pharmaceutical preparation Substances 0.000 claims description 15
• 206010016654 Fibrosis Diseases 0.000 claims description 14
• 230000004761 fibrosis Effects 0.000 claims description 12
• 150000001875 compounds Chemical class 0.000 claims description 11
• 150000003839 salts Chemical class 0.000 claims description 8
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 7
• QLJYLJGYIDIJPT-UHFFFAOYSA-N 3-(4-aminophenyl)-2-methoxypropanoic acid Chemical compound COC(C(O)=O)CC1=CC=C(N)C=C1 QLJYLJGYIDIJPT-UHFFFAOYSA-N 0.000 claims description 5
• 229940125810 compound 20 Drugs 0.000 claims description 4
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
• IIPURNWXORPFKN-UHFFFAOYSA-N 3-(4-aminophenyl)-2-ethoxypropanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=C(N)C=C1 IIPURNWXORPFKN-UHFFFAOYSA-N 0.000 claims description 3
• XVEJUCGEDMCUOH-UHFFFAOYSA-N 5-amino-2,3-dihydro-1-benzofuran-7-carboxylic acid Chemical compound OC(=O)C1=CC(N)=CC2=C1OCC2 XVEJUCGEDMCUOH-UHFFFAOYSA-N 0.000 claims description 3
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 3
• 102000000536 PPAR gamma Human genes 0.000 claims description 3
• 108010016731 PPAR gamma Proteins 0.000 claims description 3
• 239000003795 chemical substances by application Substances 0.000 claims description 3
• 229940126086 compound 21 Drugs 0.000 claims description 3
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims description 2
• NWHKKDLPTKZXQK-UHFFFAOYSA-N 1,2-dioxin-4-one Chemical compound O=C1COOC=C1 NWHKKDLPTKZXQK-UHFFFAOYSA-N 0.000 claims description 2
• BTQPTCICBAYVST-UHFFFAOYSA-N 5-amino-n-hydroxy-2-methoxybenzamide Chemical compound COC1=CC=C(N)C=C1C(=O)NO BTQPTCICBAYVST-UHFFFAOYSA-N 0.000 claims description 2
• MRRAHVVJYAOMSB-UHFFFAOYSA-N 6-amino-2,2-dimethyl-1,3-benzodioxin-4-one Chemical compound NC1=CC=C2OC(C)(C)OC(=O)C2=C1 MRRAHVVJYAOMSB-UHFFFAOYSA-N 0.000 claims description 2
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
• 229940127007 Compound 39 Drugs 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• 208000005176 Hepatitis C Diseases 0.000 claims description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 206010072877 Intestinal fibrosis Diseases 0.000 claims description 2
• 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
• 230000009787 cardiac fibrosis Effects 0.000 claims description 2
• 230000007882 cirrhosis Effects 0.000 claims description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
• 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 201000002793 renal fibrosis Diseases 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 13
• QLJYLJGYIDIJPT-VIFPVBQESA-N (2s)-3-(4-aminophenyl)-2-methoxypropanoic acid Chemical compound CO[C@H](C(O)=O)CC1=CC=C(N)C=C1 QLJYLJGYIDIJPT-VIFPVBQESA-N 0.000 claims 1
• 238000000034 method Methods 0.000 description 19
• 125000000217 alkyl group Chemical group 0.000 description 4
• 0 *C(Cc1cc(N(*)*)ccc1)C(O)=O Chemical compound *C(Cc1cc(N(*)*)ccc1)C(O)=O 0.000 description 2
• SWSPYBOIOATQGN-UHFFFAOYSA-N C/[O]=C/C(Cc(cc1)ccc1N)C(O)=O Chemical compound C/[O]=C/C(Cc(cc1)ccc1N)C(O)=O SWSPYBOIOATQGN-UHFFFAOYSA-N 0.000 description 2
• JNHSDVOZNSSXGT-UHFFFAOYSA-N C/[O]=C/C(Cc1cccc(N=C)c1)C(O)=O Chemical compound C/[O]=C/C(Cc1cccc(N=C)c1)C(O)=O JNHSDVOZNSSXGT-UHFFFAOYSA-N 0.000 description 2
• CBRYXCASBQUTTA-UHFFFAOYSA-N CC/[O]=C/C(Cc1cc(N)ccc1)C(O)=O Chemical compound CC/[O]=C/C(Cc1cc(N)ccc1)C(O)=O CBRYXCASBQUTTA-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• JJSGVSDWDJQFQR-UHFFFAOYSA-N C1C(OC2=C1C=CC=C2C(=O)O)N Chemical compound C1C(OC2=C1C=CC=C2C(=O)O)N JJSGVSDWDJQFQR-UHFFFAOYSA-N 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1